Expasy logo

UniProtKB/Swiss-Prot variant pages

UniProtKB/Swiss-Prot P49770: Variant p.Ser171Phe

Translation initiation factor eIF2B subunit beta
Gene: EIF2B2
Feedback?
Variant information Variant position: help 171 The position of the amino-acid change on the UniProtKB canonical protein sequence.
Type of variant: help LP/P [Disclaimer] The variants are classified into three categories: LP/P, LB/B and US.
  • LP/P: likely pathogenic or pathogenic.
  • LB/B: likely benign or benign.
  • US: uncertain significance
Residue change: help From Serine (S) to Phenylalanine (F) at position 171 (S171F, p.Ser171Phe). Indicates the amino acid change of the variant. The one-letter and three-letter codes for amino acids used in UniProtKB/Swiss-Prot are those adopted by the commission on Biochemical Nomenclature of the IUPAC-IUB.
Physico-chemical properties: help Change from small size and polar (S) to large size and aromatic (F) The physico-chemical property of the reference and variant residues and the change implicated.
BLOSUM score: help -2 The score within a Blosum matrix for the corresponding wild-type to variant amino acid change. The log-odds score measures the logarithm for the ratio of the likelihood of two amino acids appearing by chance. The Blosum62 substitution matrix is used. This substitution matrix contains scores for all possible exchanges of one amino acid with another:
  • Lowest score: -4 (low probability of substitution).
  • Highest score: 11 (high probability of substitution).
More information can be found on the following page
Variant description: help In VWM2; with ovarian failure. Any additional useful information about the variant.
Other resources: help Links to websites of interest for the variant.


Sequence information Variant position: help 171 The position of the amino-acid change on the UniProtKB canonical protein sequence.
Protein sequence length: help 351 The length of the canonical sequence.
Location on the sequence: help IAAQALEHIHSNEVIMTIGF S RTVEAFLKEAARKRKFHVIV The residue change on the sequence. Unless the variant is located at the beginning or at the end of the protein sequence, both residues upstream (20) and downstream (20) of the variant will be shown.
Residue conservation: help The multiple alignment of the region surrounding the variant against various orthologous sequences. 
Human                         IAAQALEHIHSNEVIMT-IGFSRTVEAFLKEAARK--RKFHVIV

Mouse                         IAAQALEHIHSNEVIMT-IGYSRTVEAFLKEAARK--RKFH

Rat                           IAAQALEHIHSNEVIMT-IGFSRTVEAFLREAAQK--RKFH

Bovine                        IAAQALEHIHSNEVIMT-IGFSRTVEAFLREAARK--RKFH

Rabbit                        IAAQALEHIHSNEVIMT-IGLSRTVEAFLREAARK--RKFH

Slime mold                    VAEQAIEHIHSNETIMT-LGCSRTVEEFLKEAARK--RSFK

Baker's yeast                 IQQIAIDLIHDHEILLTPTPDSKTVLKFLITARERSNRTFT

Fission yeast                 IEVQSMDHLHSNEIILT-QGCSKTVEAFLRFAAKK--RKFS
Sequence annotation in neighborhood: help The regions or sites of interest surrounding the variant. In general the features listed are posttranslational modifications, binding sites, enzyme active sites, local secondary structure or other characteristics reported in the cited references. The "Sequence annotation in neighborhood" lines have a fixed format:
  • Type: the type of sequence feature.
  • Positions: endpoints of the sequence feature.
  • Description: contains additional information about the feature.
TypePositionsDescription
Chain 1 – 351 Translation initiation factor eIF2B subunit beta



Literature citations
Ovarian failure related to eukaryotic initiation factor 2B mutations.
Fogli A.; Rodriguez D.; Eymard-Pierre E.; Bouhour F.; Labauge P.; Meaney B.F.; Zeesman S.; Kaneski C.R.; Schiffmann R.; Boespflug-Tanguy O.;
Am. J. Hum. Genet. 72:1544-1550(2003)
Cited for: VARIANTS VWM2 PHE-171 AND GLY-213; Identification of ten novel mutations in patients with eIF2B-related disorders.
Ohlenbusch A.; Henneke M.; Brockmann K.; Goerg M.; Hanefeld F.; Kohlschutter A.; Gartner J.;
Hum. Mutat. 25:411-411(2005)
Cited for: VARIANTS VWM2 PHE-171; SER-196; VAL-200 AND GLY-213;
Disclaimer: Any medical or genetic information present in this entry is provided for research, educational and informational purposes only. They are not in any way intended to be used as a substitute for professional medical advice, diagnostic, treatment or care.